Revaprazan

Revaprazan
Clinical data
Trade namesRevanex[1]
Other namesYH1885
ATC code
  • None
Identifiers
IUPAC name
  • N-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-pyrimidinamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H23FN4
Molar mass362.452 g·mol−1
3D model (JSmol)
SMILES
  • c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C
InChI
  • InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)
  • Key:LECZXZOBEZITCL-UHFFFAOYSA-N

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea,[4] but is not approved in Europe or the United States.

References

  1. ↑ "Revaprazan". drugs.com.
  2. ↑ Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169. S2CID 41932174.
  3. ↑ Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344. S2CID 19658496.
  4. ↑ "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006. Archived from the original on April 29, 2014.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.